吉非替尼联合紫杉醇对食管癌细胞体内外生长抑制实验研究

目的：探讨吉非替尼联合紫杉醇对人食管癌细胞株Eta-109在体内外生长的影响及其可能机制。方法：按两因素析因设计试验，并应用MTT法观察单用吉非替尼、紫杉醇及联合应用对Eca-109细胞增殖的抑制作用，流式细胞术检测细胞周期和凋亡。按单因素影响设计，建立裸鼠人食管癌皮下移植瘤模型，并分为4组各10只，分别为对照组、紫杉醇组、吉非替尼组及吉非替尼＋紫杉醇联合组。经过不同处理4周后，切除瘤灶，称瘤质量，计算抑瘤率。结果：MTT法结果显示，药物干预72h后，各用药组与对照组比较，吸光度A值均减小，吉非替尼作用72h的半数抑制浓度为（1．72±0．27）μmol／L，紫杉醇的半数抑制浓度为（5．27±0．88）μmol／L。流式细胞术检测结果显示，4组G0／G1、S和G2／M期细胞比较差异均有统计学意义，P〈0．05；对照组Eca-109细胞的凋亡率为（9．69±1．42）％，紫杉醇组为（12．41±2．75）％，吉非替尼组为（22．0±4．26）％，吉非替尼＋紫杉醇联合组为（33．1±3．78）％，差异有统计学意义，P〈0．001。对照组肿瘤体积为（1．56±0．16）cm3，紫杉醇组为（0．81±0．15）cm3，吉非替尼组为（1．35±0．08）cm3，紫杉醇＋吉非替尼联合组为（O．54±0．11）cm3，差异有统计学意义，P＜0．05。结论：吉非替尼与紫杉醇合用对体内外食管癌Eta-109细胞具有显著的抑制作用，且强于药物单一作用。

Experimental study on growth inhibition of Gefitinid combined with paclitaxel on esophageal carcinoma cells in vitro and in vivo

OBJECTIVE：To observe the effect of gefitinib combined with paclitaxel on proliferation of human esopha- geal cancer cell line Eca-109 in vitro and in vivo ,and explore its possible mechanism. METHODS： By two-factor factorial design trial, MTT was used to observe gefitinib, paclitaxel alone and in combination with inhibitory effects on Eca-109 cell proliferation. FCM was used to detect cell cycle profile and apoptotic rate of Eca-109. Also designed by a single factor, to establish the transplant tumor model of human esophageal carcinoma in nude mice subcutaneously, 40 mice were randomly divided into four groups ： control group, paelitaxeI group, gefitinib group, gefitinib combined with paciitaxe group, 4 weeks later the tumor were resected and tumor weight and inhibitory rate were calculated. RESULTS： After drug intervention 72 h,A values were decreased in all groups （P=0.01） ;ICs0 of gefitinib group was （1.72±0.27） μmol/L;IC50 of paclitax- el group was （5.27±0.88） μmol/L;FCM analysis showed that the differences among the four groups of Go/G1 phase, S phase,G2/M phase cells were statistically significant; In control group, PTX group, Gefitinib group and PTX＋ Gefitinib group, the apoptosis rate of Eca-109 cells respectively were （9.69 ± 1.42） %, （ 12.41 ± 2. 75） %, （22.0 ± 4. 26） % and （33.1±3. 78）%, the differences were statistically significant （P〈 0. 001）. The tumor volume in control group, PTX group,Gefitinib group and PTX＋ Gefitinib group were （1. 56 ± 0. 16） cm3 , （0. 81 ± 0. 15） cm3 , （1. 35 ± 0. 08） cm3 , （0.54 ± 0.11） cm3 , and the differences were statistically significant （P〈 0.05）. CONCLUSION ： Gefitinib combined with paclitaxel has a significant inhibitory effect on Eca-109,and the effect is better than that with single drug.